Important Safety Warnings Seek immediate medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Signs of dehydration from vomiting or diarrhea (dizziness, decreased urination, extreme thirst) Symptoms of gallbladder disease (right upper quadrant pain, fever, yellowing of skin or eyes) Severe hypoglycemia (confusion, loss of consciousness, seizures) Allergic reactions (difficulty breathing, swelling of face or throat, severe rash) Vision changes (if diabetic) Rapid or irregular heartbeat with chest discomfort Do not use semaglutide if you have: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known hypersensitivity to semaglutide or any formulation components Pregnancy or plans to become pregnant (discontinue at least 2 months before conception) Use with caution if you have: History of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, kidney disease, or are taking insulin or sulfonylureas
Graphical abstract Similar content being viewed by others Background Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for more than 90% of all liver cancer cases
Research investigations commonly explore the compound in experimental models examining: Peptide signalling pathways Regulatory network interactions Peptide interaction dynamics Intracellular signalling mechanisms Comparative peptide research Molecular signalling pathway analysis Receptor interaction modelling Research Applications In controlled research environments, GHK-Cu may be utilised in experimental models designed to explore peptide signalling systems and molecular interactions
Recommendation 2
So tirzepatide may actually be easier to tolerate at therapeutic doses
